PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Thoracic Diseases

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Pathology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions
Exam Review

Key Facts: Egyptian Board Thoracic Diseases Exam

Part 1 & 2

Written Exam Stages

Part 3

Clinical & OSCE Stage

Angoff / Hofstee

Standard-Setting Method

5 Years

Residency Training Duration

The Egyptian Board in Thoracic Diseases (EHC-EB-THOR) certification is the definitive specialty qualification awarded by the Egyptian Health Council (EHC) pursuant to Law No. 12 of 2022 and Decree No. 3798 of 2023. Trainees complete a structured 5-year residency and sit three assessment gates: Part One (applied basic sciences), Part Two (clinical thoracic diseases written MCQ), and Part Three (clinical OSCE and oral cases). While Part Three evaluates bedside procedural, PFT, and patient-interaction skills, this 100-question practice bank packages Part 1 and Part 2 into an English-language study aid for pulmonary diagnostic criteria, spirometry curves, and guideline-directed respiratory care; it is not a simulation of the clinical OSCE and does not replace supervised clinical practice.

Sample Egyptian Board Thoracic Diseases Practice Questions

Try these sample questions to review concepts for the Egyptian Board Thoracic Diseases exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 28-year-old healthy male breathing room air (FiO2 0.21) at sea level (barometric pressure 760 mmHg) has an arterial blood gas showing PaCO2 40 mmHg and PaO2 95 mmHg. Assuming a respiratory quotient (R) of 0.8 and water vapor pressure of 47 mmHg, what is the calculated alveolar oxygen tension (PAO2)?
A.100 mmHg
B.150 mmHg
C.85 mmHg
D.115 mmHg
Explanation: According to the alveolar gas equation: PAO2 = [FiO2 × (P_atm - P_H2O)] - (PaCO2 / R). At sea level breathing ambient air, PAO2 = [0.21 × (760 - 47)] - (40 / 0.8) = (0.21 × 713) - 50 = 149.7 - 50 ≈ 100 mmHg. This normal value yields an alveolar-arterial (A-a) oxygen gradient of 100 - 95 = 5 mmHg, which is well within normal limits for a young adult.
2A 24-year-old man is brought to the emergency department following an accidental opioid overdose. Arterial blood gas on room air shows pH 7.22, PaCO2 68 mmHg, PaO2 58 mmHg, and HCO3- 27 mEq/L. His calculated alveolar-arterial (A-a) oxygen gradient is 7 mmHg. What is the primary underlying mechanism of this patient's hypoxemia?
A.Right-to-left anatomical shunt
B.Pure alveolar hypoventilation
C.Severe ventilation-perfusion mismatch
D.Impaired alveolar-capillary diffusion
Explanation: Alveolar hypoventilation produces hypercapnia and secondary hypoxemia with a characteristically normal alveolar-arterial (A-a) gradient (normal expected gradient < 10-15 mmHg in young adults). With PAO2 = [0.21 × (760 - 47)] - (68 / 0.8) = 150 - 85 = 65 mmHg, the patient's A-a gradient is 65 - 58 = 7 mmHg. Opioids depress central respiratory drive, reducing alveolar ventilation without causing intrinsic alveolar-capillary membrane or parenchymal lung pathology.
3A 55-year-old intubated woman with severe acute respiratory distress syndrome (ARDS) secondary to bacterial sepsis has an arterial blood gas on FiO2 1.0 showing pH 7.31, PaCO2 46 mmHg, and PaO2 82 mmHg. Despite escalating FiO2 from 0.60 to 1.0, her PaO2 increased by only 8 mmHg. What is the fundamental physiological disturbance explaining this refractory hypoxemia?
A.High physiological dead space fraction (Vd/Vt > 0.60)
B.Marked rightward shift of the oxyhemoglobin dissociation curve
C.Intrapulmonary shunt with non-ventilated, perfused alveoli
D.Decreased systemic oxygen extraction ratio
Explanation: True intrapulmonary shunt (V/Q = 0) occurs when blood traverses alveolar capillaries without encountering ventilated gas spaces, as in extensive alveolar flooding, atelectasis, or consolidation in ARDS. Unlike low V/Q units, true shunted blood cannot be oxygenated even with 100% inspired oxygen because the gas never contacts the flowing erythrocytes. Consequently, administration of FiO2 1.0 fails to significantly augment arterial PaO2 in patients with large shunt fractions.
4In a mechanically ventilated patient receiving positive end-expiratory pressure (PEEP) of 16 cmH2O who develops acute hypovolemia, West Zone 1 conditions become prominent across the non-dependent lung regions. Which pressure relationship defines this West Zone?
A.Arterial pressure > Venous pressure > Alveolar pressure (Pa > Pv > PA)
B.Arterial pressure > Alveolar pressure > Venous pressure (Pa > PA > Pv)
C.Venous pressure > Alveolar pressure > Arterial pressure (Pv > PA > Pa)
D.Alveolar pressure > Arterial pressure > Venous pressure (PA > Pa > Pv)
Explanation: West Zone 1 is characterized by the relationship PA > Pa > Pv, where alveolar gas pressure exceeds both pulmonary capillary arterial and venous pressures. This compresses the alveolar capillaries, halting microvascular blood flow and converting ventilated lung units into alveolar dead space (wasted ventilation). Under normal physiological conditions at rest, Zone 1 does not exist, but it is readily provoked by positive pressure mechanical ventilation, high PEEP, or severe hypovolemic hypotension.
5During spontaneous upright respiration in a healthy adult, what is the primary driving pressure gradient governing pulmonary microvascular blood flow in West Zone 2 (mid-lung zones)?
A.Arterial pressure minus alveolar pressure (Pa - PA)
B.Arterial pressure minus venous pressure (Pa - Pv)
C.Alveolar pressure minus venous pressure (PA - Pv)
D.Pulmonary capillary wedge pressure minus left atrial pressure
Explanation: In West Zone 2, the pressure hierarchy is Pa > PA > Pv. Because alveolar pressure exceeds pulmonary venous pressure, the collapsible alveolar vessels are partially compressed at their downstream venous end, functioning as a Starling resistor or 'waterfall.' Consequently, flow is determined strictly by the upstream arterial pressure minus the surrounding alveolar pressure (Pa - PA), completely independent of downstream venous pressure.
6In an upright resting individual, regional differences in ventilation and perfusion exist throughout the lung. How do the ventilation-perfusion ratio (V/Q), alveolar PO2, and alveolar PCO2 differ in the lung apex compared to the base?
A.Apex has lower V/Q, lower PAO2, and higher PACO2
B.Apex has higher V/Q, higher PAO2, and lower PACO2
C.Apex has higher V/Q, lower PAO2, and higher PACO2
D.Apex has lower V/Q, higher PAO2, and lower PACO2
Explanation: Both ventilation and perfusion decrease from base to apex in the upright lung due to gravity, but perfusion decreases far more steeply than ventilation. As a result, the V/Q ratio is highest at the apex (~3.3) and lowest at the base (~0.63). The high apical V/Q ratio causes apical alveolar gas to approach inspired gas composition, resulting in a higher PAO2 (~130 mmHg) and a lower PACO2 (~28 mmHg) compared to the lung bases.
7A 62-year-old man with severe chronic obstructive pulmonary disease presents with acute worsening dyspnea. His baseline PaO2 is 52 mmHg on room air. Administration of 100% inspired oxygen via a non-rebreather mask for 20 minutes increases his PaO2 to 380 mmHg. What physiological conclusion can be drawn from this hyperoxia test?
A.The hypoxemia is driven by a large fixed anatomical right-to-left shunt
B.The patient has completely normal alveolar capillary diffusion kinetics
C.The hypoxemia is primarily caused by ventilation-perfusion mismatch rather than true shunt
D.The alveolar-arterial oxygen gradient has fully normalized to zero
Explanation: A robust rise in arterial PaO2 (typically above 300-400 mmHg) during 100% oxygen inhalation confirms that the underlying mechanism of hypoxemia is ventilation-perfusion (V/Q) inequality rather than a fixed right-to-left shunt. In units with low V/Q ratios, breathing 100% oxygen replaces alveolar nitrogen with oxygen, overcoming relative underventilation. In contrast, true anatomical or absolute capillary shunts (V/Q = 0) bypass ventilated alveoli entirely, preventing PaO2 from reaching high levels.
8A 58-year-old mechanically ventilated patient has mixed expired carbon dioxide tension (PeCO2) measured at 20 mmHg, while concurrent arterial blood gas reveals PaCO2 of 50 mmHg. Tidal volume is set at 500 mL. Using the Enghoff modification of the Bohr equation, what is the patient's physiological dead space volume (Vd)?
A.150 mL
B.200 mL
C.250 mL
D.300 mL
Explanation: The Enghoff modification of the Bohr equation calculates the physiological dead space fraction: Vd/Vt = (PaCO2 - PeCO2) / PaCO2. Substituting the values: Vd/Vt = (50 - 20) / 50 = 30 / 50 = 0.60 (60%). With a tidal volume (Vt) of 500 mL, the absolute physiological dead space volume is 0.60 × 500 mL = 300 mL. Normal physiological dead space fraction in healthy conscious adults is approximately 0.20 to 0.33 (20-33%).
9During vigorous physical exercise, working skeletal muscles generate heat, carbon dioxide, and lactic acid. How do these local metabolic alterations affect the oxyhemoglobin dissociation curve, and what is the physiological advantage?
A.Rightward shift (Bohr effect), facilitating oxygen unloading to active muscle tissue
B.Leftward shift, increasing oxygen affinity to prevent tissue hypoxia
C.Rightward shift, increasing the total oxygen-carrying capacity of hemoglobin
D.Leftward shift (Haldane effect), accelerating carbon dioxide clearance into the blood
Explanation: Elevations in temperature, hydrogen ion concentration (acidosis/low pH), PaCO2, and erythrocyte 2,3-bisphosphoglycerate (2,3-BPG) cause a rightward shift of the oxyhemoglobin dissociation curve (the Bohr effect). This increases the P50 (partial pressure of oxygen required to achieve 50% hemoglobin saturation), reducing hemoglobin's oxygen affinity at tissue capillary level and enhancing the unloading of bound oxygen to metabolically active, exercising tissues.
10A 68-year-old man with severe COPD and chronic baseline PaCO2 of 54 mmHg is admitted with an acute exacerbation. He is mistakenly placed on FiO2 0.50 via a Venturi mask, after which his PaO2 rises to 110 mmHg and his PaCO2 escalates to 72 mmHg with acute respiratory acidosis. Which physiological mechanism best describes the Haldane effect contributing to this acute hypercapnia?
A.Abolition of the peripheral hypoxic respiratory drive in the carotid bodies
B.Oxygenation of hemoglobin displacing carbon dioxide and protons from amino groups, releasing dissolved CO2 into blood
C.Worsening alveolar dead space due to absorption atelectasis in unventilated lung bases
D.Competitive inhibition of carbonic anhydrase by high molecular oxygen concentrations
Explanation: The Haldane effect describes the property of hemoglobin wherein deoxygenated hemoglobin has a greater affinity for carbon dioxide (forming carbamino compounds) and protons than oxygenated hemoglobin. When high-flow supplemental oxygen oxygenates hemoglobin, it displaces bound CO2 into solution as dissolved gas, acutely increasing blood PaCO2. In hypercapnic COPD, this Haldane shift, alongside relief of hypoxic pulmonary vasoconstriction (worsening V/Q mismatch), accounts for the majority of oxygen-induced hypercapnia.

About the Egyptian Board Thoracic Diseases Exam

The Egyptian Board in Thoracic Diseases is the premier national specialty certification conferred by the Egyptian Health Council under Law No. 12 of 2022. It assesses mastery of applied basic respiratory sciences (Part 1), comprehensive clinical pulmonology and pharmacotherapy (Part 2), and advanced clinical bedside and OSCE performance (Part 3). This practice question bank is an English-language study aid focused on written cognitive knowledge, pulmonary diagnostic criteria, spirometry curves, and guideline-directed respiratory care.

Exam sponsor: Egyptian Health Council — Egyptian Board. The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Thoracic Diseases (البورد المصري في الأمراض الصدرية) is governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The 5-year structured training pathway consists of three examination tiers: Part One (applied basic medical sciences: pulmonary physiology, respiratory mechanics, gas exchange, lung pathology, and respiratory pharmacology, held in March and August); Part Two (advanced clinical thoracic medicine single-best-answer written MCQs, held in April and September); and Part Three (clinical OSCE, spirometry/PFT and chest imaging stations, oral viva, and structured clinical cases, held in December and January). Written papers are scored using psychometric standard-setting methods (Angoff/Modified Angoff or Hofstee), while Part Three uses the Borderline Regression Method.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Egyptian candidates pay EGP 1,500 on first attempt (rising to EGP 8,000 on repeated attempts) for Part One and Part Two, and EGP 4,000 to EGP 9,000 for Part Three clinical examinations. Non-Egyptian candidates pay EGP 6,000 to EGP 16,000 per stage.

Exam sponsor website

Reported exam pass rate: Determined annually through criterion-referenced standard-setting committees; not publicly released as a fixed time-series.. EHC establishes passing thresholds for each sitting using psychometric standard-setting panels rather than arbitrary numerical cutoffs. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

15% of exam

Pulmonary Physiology and Gas Exchange (Part One)

Alveolar gas equation, ventilation-perfusion relationships, diffusion capacity (DLCO), oxygen and carbon dioxide transport, oxyhemoglobin dissociation, and control of breathing.

15% of exam

Lung Mechanics, Ventilation, and Diagnostic PFT (Part One)

Static and dynamic lung compliance, airway resistance, work of breathing, flow-volume loops, spirometry interpretation, plethysmography, and lung volumes (TLC, FRC, RV).

10% of exam

Respiratory Anatomy, Pathology, and Pharmacology (Part One)

Tracheobronchial anatomy, mediastinal compartments, thoracic lymph node stations, pulmonary histopathology, bronchodilators, corticosteroids, biologics, and antimycobacterial agents.

12% of exam

Obstructive Airway Diseases (Asthma and Bronchiectasis) (Part Two)

GINA guideline stepwise pharmacotherapy, SMART/MART strategy, acute severe asthma protocols, severe refractory asthma phenotyping, bronchiectasis etiology, and cystic fibrosis.

12% of exam

Chronic Obstructive Pulmonary Disease and Respiratory Failure (Part Two)

GOLD guideline classifications (ABE groups), acute COPD exacerbation management, long-term oxygen therapy (LTOT), non-invasive positive pressure ventilation (NIV), and ARDS ventilatory strategies.

12% of exam

Interstitial Lung Diseases, IPF, and Sarcoidosis (Part Two)

ATS/ERS/JRS/ALAT guidelines for idiopathic pulmonary fibrosis (IPF), HRCT patterns (UIP vs NSIP), antifibrotic therapy, hypersensitivity pneumonitis, CTD-associated ILD, and sarcoidosis staging.

10% of exam

Pulmonary Vascular Diseases and Thromboembolism (Part Two)

Pulmonary hypertension diagnostic hemodynamics (right heart catheterization, Groups 1-5), acute pulmonary embolism risk stratification (sPESI), systemic thrombolysis, and CTEPH evaluation.

14% of exam

Thoracic Oncology, Pleural Diseases, and Interventional Pulmonology (Part Two)

Lung cancer TNM staging and molecular driver mutations, solitary pulmonary nodules, pleural effusion analysis via Light's criteria, pneumothorax management, and diagnostic bronchoscopy (EBUS-TBNA).

Preparing for the Egyptian Board Thoracic Diseases Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board in Thoracic Diseases (البورد المصري في الأمراض الصدرية) is governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The 5-year structured training pathway consists of three examination tiers: Part One (applied basic medical sciences: pulmonary physiology, respiratory mechanics, gas exchange, lung pathology, and respiratory pharmacology, held in March and August); Part Two (advanced clinical thoracic medicine single-best-answer written MCQs, held in April and September); and Part Three (clinical OSCE, spirometry/PFT and chest imaging stations, oral viva, and structured clinical cases, held in December and January). Written papers are scored using psychometric standard-setting methods (Angoff/Modified Angoff or Hofstee), while Part Three uses the Borderline Regression Method.
  • Time limit: Varies by examination part
  • Exam / certification fees: Egyptian candidates pay EGP 1,500 on first attempt (rising to EGP 8,000 on repeated attempts) for Part One and Part Two, and EGP 4,000 to EGP 9,000 for Part Three clinical examinations. Non-Egyptian candidates pay EGP 6,000 to EGP 16,000 per stage. Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Thoracic Diseases: Suggested Study Strategy

1Master pulmonary physiology and PFT curve interpretation: understand the physiological mechanisms underlying changes in FEV1/FVC ratios, flow-volume loop configurations, DLCO reductions, and alveolar-arterial oxygen gradients.
2Align clinical management with current international and EHC guideline matrices, specifically GOLD for COPD, GINA for asthma, and ATS/ERS for idiopathic pulmonary fibrosis and pulmonary hypertension.
3Review high-yield chest CT imaging patterns: differentiating definite UIP from NSIP, organizing pneumonia, sarcoidosis perilymphatic nodules, and distinguishing exudative from transudative pleural effusions via Light's criteria.
4Focus on guideline-directed therapeutics, dosing rationales, adverse effect profiles, and contraindications for biologics in severe asthma, antifibrotics in IPF, and pulmonary vasodilators in pulmonary arterial hypertension.
5Practice timed single-best-answer questions to build diagnostic efficiency when interpreting clinical vignettes featuring complex spirometric values and arterial blood gas panels.

Frequently Asked Questions

What is the official structure of the Egyptian Board in Thoracic Diseases?

The Egyptian Board certification under the Egyptian Health Council (EHC) consists of three examination tiers: Part One evaluates applied basic sciences (pulmonary physiology, mechanics, anatomy, pathology, and pharmacology); Part Two assesses advanced clinical thoracic diseases through single-best-answer written MCQs; and Part Three consists of a clinical OSCE, spirometry/PFT and chest imaging stations, oral viva boards, and bedside patient cases.

How are passing standards determined for Egyptian Board examinations?

The Egyptian Health Council employs criterion-referenced psychometric standard-setting methodologies rather than arbitrary percentage cutoffs. Written papers in Part One and Part Two are set using Angoff, Modified Angoff, or Hofstee methods, while the Part Three clinical OSCE uses the Borderline Regression Method.

Does this question bank simulate the Part Three clinical examination?

No. Part Three of the Egyptian Board is a multi-day clinical examination consisting of practical OSCE stations, slide-based OSPE, oral examinations, and real patient case evaluations. This 100-question multiple-choice bank is an English-language study aid tailored to the cognitive knowledge, spirometry curves, imaging criteria, and guideline-directed care tested in Part One and Part Two.

What legal framework governs the Egyptian Board in Thoracic Diseases?

The Egyptian Board (formerly the Egyptian Fellowship) is established under Egyptian Health Council Law No. 12 of 2022 and its Executive Regulations promulgated by Prime Ministerial Decree No. 3798 of 2023, unifying specialty postgraduate medical training and certification across Egypt.

When are the Egyptian Board thoracic diseases examinations administered?

Part One written examinations take place twice annually in March and August; Part Two clinical written examinations are held in April and September; and Part Three clinical/OSCE examinations are administered annually in December and January.

What are the core topics tested in Part One versus Part Two?

Part One concentrates on core foundation sciences: respiratory physiology (gas exchange, V/Q ratios, DLCO), respiratory mechanics (compliance, resistance, lung volumes), pulmonary pathology, and respiratory pharmacology. Part Two concentrates on clinical disease management: COPD (GOLD guidelines), bronchial asthma (GINA), interstitial lung diseases and IPF, pulmonary hypertension, acute pulmonary embolism, lung cancer staging and oncogenes, pleural effusions, sleep apnea, and mycobacterial infections.